The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price is racing higher on Friday after the release of its fourth quarter update.
At the time of writing the pharmaceutical company’s shares are up 4% to $23.26.
How did CLINUVEL perform in the fourth quarter?
During the fourth quarter of FY 2020, CLINUVEL recorded cash receipts of $10.4 million. While this was almost double the cash receipts of $5.37 million it achieved in the prior quarter, this was largely down to seasonal factors.
The company’s SCENESSE product is used to treat erythropoietic protoporphyria (EPP), a disease that causes itching, burning, and scarring of the skin on contact with sunlight. Given that the company has a focus on the Northern Hemisphere market, its sales are strongest during its spring and summer periods.
In comparison to the prior corresponding period, cash receipts actually declined 20% from $13 million.
Management notes that many of the countries in which CLINUVEL operates are still experiencing lockdowns and disruptions to daily life and commercial operations. This led to some clinics either deferring orders or reducing order sizes in the initial months of the COVID infections.
Nevertheless, despite the lower cash receipts, the company generated positive cash flow for the quarter. Net cash flow for the quarter came in at $7.2 million, lifting its cash and equivalents on hand by 7% over the quarter to $66.75 million.
Demand largely unaffected.
CLINUVEL’s Chief Financial Officer, Darren Keamy, revealed that demand remained strong despite the pandemic.
He said: “Against the global economic contraction, CLINUVEL is best positioned to invest in its planned growth and expansion, and patient demand for treatment has been largely unaffected, a testament to the impact of EPP on patients’ lives and their need for ongoing treatment.”
“Looking back, we have had a clear, long-held, view on how to optimise our resources and prepare for adverse economic conditions. By maintaining a strong cash position, we are able to respond to changes quickly and nimbly, limiting the need to return to investors to access capital and allowing us to focus on the long-term growth of the Group,” Mr Keamy said.
5 stocks under $5
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
- These are the 10 most shorted shares on the ASX
- These are the 10 most shorted shares on the ASX
- ASX 200 jumps 1.3%: Big four banks drop lower, Afterpay up after U.S. update
- Here are the 10 most shorted shares on the ASX
- These are 10 most shorted shares on the ASX
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post CLINUVEL share price races higher on Q4 update appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2BO753M
Leave a Reply